Stay updated on Nivolumab vs Docetaxel in NSCLC: Clinical Trial

Sign up to get notified when there's something new on the Nivolumab vs Docetaxel in NSCLC: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab vs Docetaxel in NSCLC: Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The page now presents the CheckMate 078 study record, including its completed status, eligibility criteria, study design, interventions, and outcome measures.
    Difference
    63%
    Check dated 2026-11-08T01:12:03.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T19:59:12.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    A site-wide NIH announcement banner appears, linking to transition updates and describing the agency’s terminology change from “Artificial Intelligence” to “Super Intelligence.”
    Difference
    1%
    Check dated 2026-10-24T22:31:47.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The footer site revision changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T22:40:20.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1 while the page remains a 403 error page.
    Difference
    0.2%
    Check dated 2026-10-10T22:28:02.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The page now renders a 403 Forbidden error page with the HTML shell (doctype and meta tags) and a 403 title, indicating the study page is currently inaccessible. A Home link and a revision note are displayed as part of the error page.
    Difference
    18%
    Check dated 2026-09-19T22:06:05.000Z thumbnail image

Stay in the know with updates to Nivolumab vs Docetaxel in NSCLC: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Docetaxel in NSCLC: Clinical Trial page.